Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 59
Filter
1.
J Clin Endocrinol Metab ; 97(6): 2077-83, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22492870

ABSTRACT

OBJECTIVE: Pheochromocytomas are characterized by a high attenuation value on unenhanced computed tomography (CT). It is not known whether pheochromocytoma could be ruled out as a cause of adrenal incidentalomas on the basis of unenhanced attenuation values only. DESIGN: We retrospectively evaluated the outcome of routine biochemical screening for pheochromocytoma in a series of adrenal incidentalomas in relationship to the unenhanced attenuation values on CT. METHODS: An unenhanced CT was available in 174 of 184 patients with 214 adrenal incidentalomas. All patients were screened for pheochromocytoma with 24-h urinary metanephrines and normetanephrines and for hypercortisolism (1 mg dexamethasone test and ACTH). Hypertensive patients were screened for aldosterone overproduction (aldosterone to renin ratio and 24 h urinary aldosterone). The results were compared between incidentalomas with high [≥10 Hounsfield units (HU)] and low (<10 HU) unenhanced attenuation values. RESULTS: One hundred forty-six incidentalomas in 115 patients had an unenhanced HU less than 10. None of these patients had elevated 24-h fractionated urinary metanephrines or normetanephrines suggesting pheochromocytoma. Sixty-eight incidentalomas in 59 patients had an unenhanced HU of 10 or greater, and nine (15.2%) of these patients had surgically and histologically verified pheochromocytoma. Incidentalomas with a HU of 10 or greater were significantly larger (2.6 ± 1.5 vs. 2.3 ± 1.2 cm; P < 0.001), more often functional (27.9 vs. 8.9%, P < 0.001), and more often operated (44.1 vs. 10.2%; P < 0.001) than those with a Hounsfield unit less than 10. CONCLUSION: The results of this study indicate that routine biochemical screening of pheochromocytoma in small homogenous adrenal incidentalomas characterized by an unenhanced Hounsfield unit value less than 10 HU may not be necessary.


Subject(s)
Adrenal Gland Neoplasms/diagnostic imaging , Adrenal Gland Neoplasms/metabolism , Mass Screening , Pheochromocytoma/diagnostic imaging , Pheochromocytoma/metabolism , Tomography, X-Ray Computed , Abdominal Pain/diagnostic imaging , Abdominal Pain/epidemiology , Adrenal Gland Neoplasms/epidemiology , Adrenocorticotropic Hormone/blood , Adult , Aged , Aged, 80 and over , Asymptomatic Diseases/epidemiology , Female , Follow-Up Studies , Humans , Hydrocortisone/blood , Incidental Findings , Male , Mass Screening/statistics & numerical data , Metanephrine/urine , Middle Aged , Normetanephrine/urine , Pheochromocytoma/epidemiology , Retrospective Studies , Tomography, X-Ray Computed/statistics & numerical data , Unnecessary Procedures/statistics & numerical data , Young Adult
2.
Diabet Med ; 25(5): 570-7, 2008 May.
Article in English | MEDLINE | ID: mdl-18445170

ABSTRACT

AIMS: Diabetic gastroparesis is a common condition occurring in some 30-50% of patients with long-term diabetes. Some studies have found a relationship between autonomic neuropathy and diabetic gastroparesis. In addition to autonomic neuropathy, acute changes in plasma glucose concentration can also affect gastric emptying. The objective was to examine the relationship between autonomic nerve function, glucose concentration, gastric emptying, and upper abdominal symptoms in Type 1 diabetic patients. METHODS: Gastric emptying of solids and liquids was measured with scintigraphy in 27 patients with longstanding Type 1 diabetes with upper abdominal symptoms. Autonomic nerve function was examined by standardized cardiovascular tests, and plasma glucose concentrations were measured during scintigraphy. Severity of abdominal symptoms and quality of life were explored by validated questionnaires. RESULTS: Seven patients (26%) had delayed gastric emptying of solids and three (11%) of liquids. Mean gastric half-emptying time of solids was 128 +/- 116 min and of liquids 42 +/- 30 min. Of the 26 patients undergoing tests, 16 (62%) had autonomic nerve dysfunction. Autonomic neuropathy score (1.6 +/- 1.7) correlated positively with the gastric emptying rate of solids (P = 0.006), a rate unrelated to symptom scores or plasma glucose concentrations during scintigraphy. Quality of life in patients with abdominal symptoms was lower than in the normal Finnish population. CONCLUSIONS: Impaired gastric emptying of solids in patients with Type 1 diabetes is related to autonomic neuropathy, but not to actual glycaemic control. The upper abdominal symptoms observed in these patients cannot be explained, however, by impaired gastric emptying.


Subject(s)
Diabetes Mellitus, Type 1/complications , Diabetic Neuropathies/complications , Gastric Emptying/physiology , Gastroparesis/etiology , Abdominal Pain/etiology , Abdominal Pain/physiopathology , Adult , Blood Glucose/metabolism , Diabetes Mellitus, Type 1/physiopathology , Diabetic Neuropathies/physiopathology , Female , Gastroparesis/diagnostic imaging , Gastroparesis/physiopathology , Glycated Hemoglobin/metabolism , Humans , Male , Quality of Life , Radionuclide Imaging , Radiopharmaceuticals , Recurrence , Technetium Tc 99m Pentetate
3.
Eur J Endocrinol ; 157(3): 285-94, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17766710

ABSTRACT

OBJECTIVE: The existence of genotype-phenotype correlation in multiple endocrine neoplasia type 1 (MEN1) is controversial. Two founder mutations of the MEN1 gene in Northern Finland gave us an opportunity to compare clinical features among heterozygotes of different mutations. DESIGN AND METHODS: Study cohort included 82 MEN1 heterozygotes who were tested for MEN1 during the years 1982-2001. Medical records were reviewed for manifestations of MEN1, other tumours and cause of death by the end of August 2003. Logistic regression analysis was used in evaluating the impact of age, gender and mutational status of affected heterozygotes on the likelihood of developing manifestations of MEN1. RESULTS: Founder mutations 1466del12 and 1657insC were found in 39 and 29 individuals, and D418N, G156R and R527X mutations in 9, 3 and 2 individuals respectively. Except for pituitary adenoma and nonfunctional pancreatic tumour (NFPT), age was a risk factor for all the disease manifestations. For NFPT, frameshift/nonsense mutations (1657insC, R527X) gave an odds ratio (OR) of 3.26 (95% confidence intervals (CI), 1.27-8.33; P = 0.014) compared with in-frame/missense mutations (1466del12, D418N, G156R); including the founder mutation carriers (n = 68) only, the 1657insC mutation gave an OR of 3.56 (CI, 1.29-9.83; P = 0.015). For gastrinoma, in-frame/missense mutations predicted the risk with an OR of 6.77 (CI, 1.31-35.0; P = 0.022), and in the founder mutations group the 1466del12 mutation gave an OR of 15.09 (CI, 1.73-131.9, P = 0.014). CONCLUSIONS: In this study population, NFPT was more common in the frameshift/nonsense or 1657insC mutation carriers, whereas gastrinoma was more common in the in-frame/missense or 1466del12 mutation carriers.


Subject(s)
Multiple Endocrine Neoplasia Type 1/genetics , Multiple Endocrine Neoplasia Type 1/mortality , Proto-Oncogene Proteins/genetics , Adolescent , Adrenal Gland Neoplasms/genetics , Adrenal Gland Neoplasms/mortality , Adult , Aged , Carcinoma, Neuroendocrine/genetics , Carcinoma, Neuroendocrine/mortality , Child , Codon, Nonsense , Female , Finland/epidemiology , Founder Effect , Frameshift Mutation , Gastrointestinal Neoplasms/genetics , Gastrointestinal Neoplasms/mortality , Genotype , Humans , Hyperparathyroidism, Primary/genetics , Hyperparathyroidism, Primary/mortality , Male , Middle Aged , Mutation, Missense , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/mortality , Phenotype , Pituitary Neoplasms/genetics , Pituitary Neoplasms/mortality , Risk Factors
4.
Diabet Med ; 24(1): 87-90, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17227329

ABSTRACT

AIMS: To determine how young adults with insulin therapy manage daily care of diabetes during the physically demanding conditions of conscript military service, and to evaluate the effects of military service on glycaemic control and on the incidence of acute diabetic complications. METHODS: An observational study of 47 young male volunteer conscripts receiving insulin therapy was carried out at the Signal Regiment in Riihimäki from January 2001 to July 2005. Outcome measures were drop-out rate from service, management of diabetes care, glycaemic control, and occurrence of severe hypoglycaemia or ketoacidosis during service. RESULTS: Forty (85%) diabetic conscripts completed service, with service time ranging from 180 to 362 days, and seven (15%) interrupted service. One-third of conscripts reported difficulties during military training with insulin injections and blood glucose testing. The mean HbA(1c) during service increased by 0.6% units (P = 0.007) from baseline. Five events of severe hypoglycaemia in three conscripts (overall incidence rate 0.15 per patient-year) and one ketoacidosis event occurred. Diabetic conscripts were chosen for leadership training more often than non-diabetic conscripts. CONCLUSIONS: Our data suggest that selected and motivated adolescents on insulin therapy can manage the daily care of diabetes and maintain appropriate glycaemic control during service, although the risk of severe hypoglycaemia exists.


Subject(s)
Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/therapeutic use , Insulin, Isophane/therapeutic use , Military Personnel , Adolescent , Adult , Blood Glucose Self-Monitoring/methods , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/epidemiology , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/epidemiology , Finland/epidemiology , Humans , Hypoglycemia/epidemiology , Hypoglycemia/etiology , Male , Risk Factors
5.
Scand J Clin Lab Invest ; 66(2): 147-59, 2006.
Article in English | MEDLINE | ID: mdl-16537248

ABSTRACT

OBJECTIVE: Measurement of urinary free tetrahydrocortisol and tetrahydrocortisone ratio (allo-THF+THF)/THE is clinically important in the diagnosis of hypertension caused by congenital absence of 11beta-hydroxysteroid dehydrogenase type 2 (apparent mineralocorticoid excess, AME) or inhibition of the enzyme after licorice ingestion. Although gas chromatography-mass spectrometry (GC-MS) provides reliable results, it requires derivatization and is lengthy and time-consuming. The purpose of this study was to demonstrate that detection by liquid chromatography-mass spectrometry (LC-MS) is a potentially superior method. MATERIAL AND METHODS: The analysis utilizes 1 mL urine. The samples were extracted with solid-phase extraction (SPE) using ethyl acetate as eluent. The extract was evaporated to dryness, and allo-tetrahydrocortisol (allo-THF), THF and THE concentrations were analyzed by LC-MS/MS operating in the negative mode after separation on a reversed-phase column. The calibration curves exhibited consistent linearity and reproducibility in the range of 7.5-120 nmol/L. Interassay CVs were 7.0-10 % at mean ratios of (allo-THF+THF)/THE of 0.54-1.9. The detection limit of the analytes was 0.4-0.8 nmol/L (signal-to-noise ratio = 3). The mean recovery of the three analytes ranged from 88 to 95 %. The regression equation for the free ratio using the LC-MS/MS (x) method and the total ratio using the GC-MS (y) method was: y = 0.30x+0.91 (r = 0.61; n = 25). CONCLUSIONS: The sensitivity and specificity of the LC-MS/MS method offer an advantage over GC-MS by eliminating derivatization. The high costs of equipment are balanced by higher through-put, owing also to shorter chromatographic run times.


Subject(s)
Chromatography, Liquid/methods , Mass Spectrometry/methods , Mineralocorticoid Excess Syndrome, Apparent/diagnosis , Tetrahydrocortisol/urine , Tetrahydrocortisone/urine , Humans
6.
Diabetes Res Clin Pract ; 71(2): 131-9, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16054266

ABSTRACT

Insulin aspart has been shown, in medium-term studies, to achieve reductions in HbA(1c) without increasing the risk of major hypoglycaemia compared with pre-meal human insulin. The aim of the present 3-year study was to evaluate the long-term safety and efficacy of insulin aspart in people with type 1 diabetes. This was a 30-month extension of a multinational, multicentre, open-label, parallel-group study of 753 people with type 1 diabetes, originally randomly allocated to treatment with insulin aspart or unmodified human insulin before meals, with NPH insulin as basal insulin. Main outcomes measures were hypoglycaemia (major or minor), adverse events and HbA(1c). As insulin aspart became commercially available in some countries before the end of the trial, analyses of HbA(1c) used 30-month data to maintain statistical power. The relative risk estimate of major hypoglycaemia was similar between treatment groups (relative risk [RR] 1.00 [95% CI 0.72, 1.39]). The risk of having a minor hypoglycaemic episode was higher with insulin aspart than with human soluble insulin (RR 1.24 [1.09, 1.39] p=0.024). Insulin aspart was significantly superior to human insulin with respect to overall glycaemic control, with a baseline-adjusted HbA(1c) difference of -0.16 (-0.32, -0.01)% (p=0.035). Insulin aspart was well tolerated and effective during long-term treatment. The HbA(1c) advantage was maintained with insulin aspart without any adverse impact on the rate of major hypoglycaemia.


Subject(s)
Eating , Insulin, Isophane/therapeutic use , Insulin/analogs & derivatives , Adult , Body Mass Index , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Hypoglycemia/epidemiology , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/therapeutic use , Insulin/administration & dosage , Insulin/therapeutic use , Insulin Aspart , Insulin, Isophane/administration & dosage , Male , Middle Aged
7.
Aliment Pharmacol Ther ; 24(11-12): 1545-52, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17206943

ABSTRACT

BACKGROUND/AIM: To evaluate the safety of budesonide in primary biliary cirrhosis. METHODS: 77 primary biliary cirrhosis patients, with stages I-III at entry, were randomized to use either budesonide 6 mg and ursodeoxycholic acid 15 mg/kg (group A), or ursodeoxycholic acid alone (group B) daily for 3 years. In 22 patients, budesonide pharmacokinetics was determined after 3 years. Bone mass density was measured in 62 patients at baseline and 3 years; in 57 patients also liver biopsies were performed. RESULTS: At 3 years, no significant differences in the pharmacokinetics of budesonide were found between the patients with stages 0-I, II and III primary biliary cirrhosis. In group A, bone mass density in femoral neck and lumbar spine were decreased by 3.6% (P = 0.0002) and 2.8% (P = 0.003) from the baseline. In group B, the corresponding decreases were 1.9% (P = 0.029) and 0.7% (P = 0.25), but the differences between the groups were not statistically significant (P = 0.16 for femoral neck and P = 0.08 for lumbar spine). CONCLUSIONS: The plasma concentrations of budesonide do not significantly differ within stages I-III primary biliary cirrhosis patients. The combination of budesonide and ursodeoxycholic acid may decrease bone mass density in the femoral neck and lumbar spine in some primary biliary cirrhosis patients, and bone mass density is recommended to be monitored during budesonide therapy.


Subject(s)
Anti-Inflammatory Agents/adverse effects , Bone Density/drug effects , Budesonide/adverse effects , Liver Cirrhosis, Biliary/drug therapy , Anti-Inflammatory Agents/pharmacokinetics , Budesonide/pharmacokinetics , Female , Humans , Male , Osteoporosis/prevention & control , Treatment Outcome
8.
Int J Obes Relat Metab Disord ; 27(10): 1233-41, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14513072

ABSTRACT

OBJECTIVE: To study health-related quality of life (HRQL) in a clinically selected sample of obese outpatients. DESIGN: A single-strand before and after study with 2-y follow-up after treatment comprising 10 weeks on very-low-energy diet (VLED) and 4 months of behaviour modification in groups. SUBJECTS: A total of 126 (mean (s.d.) age 48.2 (11.1) y and body mass index 42.8 (6.2) kg/m(2) obese patients (63% women) referred for treatment in an obesity clinic. MEASUREMENTS: Weight and HRQL using questionnaires (RAND 36-Item Health Survey 1.0 and Obesity-related Psychosocial problems scale (OP-scale)). RESULTS: A total of 100 patients (61% women) completed the treatment and 67 (71% women) completed the 2-y follow-up. The mean (s.d.) weight loss was 12.5 (5.6)% at the end of group therapy, 6.0 (7.1)% at 1 y, and 2.6 (7.5)% at 2 y. At baseline, the mean (s.d.) score for the OP-scale was 61.9 (24.6). The mean scores on every RAND-36 scale were markedly lower than in the Finns without chronic conditions. All the scales in HRQL improved markedly during the treatment. During the follow-up, all the scales started to return towards baseline levels, and at 2 y only obesity-related psychosocial problems and physical functioning were still improved relative to baseline. In categories of weight change at 2 y (>or=10% weight loss, 0-9.9% weight loss, weight gain), obesity-related psychosocial functioning, physical functioning, and general health showed dose-response improvement with increasing weight loss. A >or=10% weight loss at 2 y after treatment was associated with clear improvement in obesity-related psychosocial problems, physical functioning, physical role functioning, bodily pain, general health, mental health, and vitality. A 0-9.9% weight loss was associated with improvement in obesity-related psychosocial problems and physical functioning. Weight gain was associated with improvement in obesity-related psychosocial problems and social functioning. The study population was too small to examine possible gender differences. CONCLUSIONS: Treatment with VLED and behaviour modification produces marked short-term weight loss and clear improvement in all aspects of HRQL. At 2 y after treatment, the average maintained weight loss is modest. However, 1/3 of patients maintained a >or=5% weight loss. Improvement in obesity-related psychosocial problems and physical functioning is associated even with less than 10% of maintained weight loss. Since the pattern of HRQL changes only partly followed the pattern of weight change as expected, other factors, such as the therapeutic effect of participating in the weight loss programme or increase in physical activity, may affect HRQL responses.


Subject(s)
Behavior Therapy/methods , Health Status , Obesity/therapy , Quality of Life , Age Factors , Body Mass Index , Energy Metabolism , Female , Follow-Up Studies , Humans , Male , Mental Health , Middle Aged , Obesity/diet therapy , Obesity/psychology , Patient Compliance , Physical Exertion , Psychology, Social , Sex Factors , Weight Loss
9.
Int J Obes Relat Metab Disord ; 27(9): 1072-80, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12917713

ABSTRACT

OBJECTIVE: To study health-related quality of life (HRQL) in a clinically selected sample obese outpatients. DESIGN: A single-strand before and after study with 2-y follow-up after treatment comprising 10 weeks on very-low-energy diet (VLED) and 4 months of behaviour modification in groups. SUBJECTS: A total of 126 patients (mean (s.d.) age 48.2 (11.1) y and body mass index (BMI) 42.8 (6.2) kg/m(2) (63% women)) referred for treatment in an obesity clinic. MEASUREMENTS: Weight and HRQL using questionnaires (RAND 36-Item Health Survey 1.0 and Obesity-related Psychosocial problems-scale). RESULTS: In all, 100 patients (61% women) completed the treatment and 67 (71% women) completed the 2-y follow-up. The mean (s.d.) weight loss was 12.5 (5.6)% at the end of group therapy, 6.0 (7.1)% at 1 y, and 2.6 (7.5)% at 2 y. At baseline, the mean (s.d.) score for OP-scale was 61.9 (24.6). The mean scores on every RAND-36 scale were markedly lower than in the Finns without chronic conditions. All the scales in HRQL improved markedly during the treatment. During the follow-up, all the scales started to return back towards baseline levels and at 2 y, only obesity-related psychosocial problems and physical functioning were still improved relative to baseline. In categories of weight change at 2 y (> or =10% weight loss, 0-9.9% weight loss, weight gain), obesity-related psychosocial functioning, physical functioning, and general health showed dose-response improvement with increasing weight loss. A > or =10% weight loss at 2 y after treatment was associated with clear improvement in obesity-related psychosocial problems, physical functioning, physical role functioning, bodily pain, general health, mental health, and vitality. A 0-9.9% weight loss was associated with improvement in obesity-related psychosocial problems and physical functioning. Weight gain was associated with improvement in obesity-related psychosocial problems and social functioning. The study population was too small to examine possible gender differences. CONCLUSIONS: Treatment with VLED and behaviour modification produces marked short-term weight loss and clear improvement in all aspects of HRQL. At 2 y after treatment, the average maintained weight loss is modest. However, one-third of patients maintain > or =5% weight loss. Improvement in obesity-related psychosocial problems and physical functioning is associated even with &<10% of maintained weight loss. Since the pattern of HRQL changes did only partly follow the pattern of weight change as expected, other factors, such as the therapeutic effect of participating in the weight loss programme or increase in physical activity, may affect HRQL responses.


Subject(s)
Behavior Therapy/methods , Energy Intake/physiology , Obesity/therapy , Quality of Life , Weight Loss/physiology , Adult , Chronic Disease , Female , Follow-Up Studies , Humans , Male , Middle Aged , Obesity/diet therapy , Obesity/physiopathology , Outpatients , Patient Dropouts , Psychology, Social , Time Factors
10.
Scand J Clin Lab Invest ; 62(5): 357-60, 2002.
Article in English | MEDLINE | ID: mdl-12387581

ABSTRACT

Diurnal variation in serum cortisol is nearly always absent in patients with Cushing's syndrome (CS), as shown by elevated levels of midnight serum cortisol (MSC). The sensitivity of MSC in the diagnosis of CS has been shown to be 96-100% measured on an inpatient basis. The purpose of this study was to state reference values for MSC measured on an outpatient basis in healthy non-sleeping controls, and to calculate the sensitivity and specificity of the test in patients with verified CS based on these data. Thirty-six healthy volunteers (11 males, 25 females) with a median age of 40.5 (range 22-60) years and a mean body mass index (BMI) of 27.0+/-5.9kg/m2 were included in the study. Serum cortisol was measured at 24.00h. In 35 CS patients (5 males, 30 females) with a median age of 44.5 (range 23-79) years and mean BMI of 28.5+/-6.9 kg/m2, MSC was measured on the first night after admission to hospital, in a non-sleeping state. All controls, with the exception of one, had MSC values below 200nmol/L. One CS patient showed an MSC level below 200nmol/L. Based on these observations, the sensitivity and specificity of the test were 97.1% and 97.2%, respectively, when 200nmol/L was used as the cut-off limit. Non-sleeping state does not seem to compromise the sensitivity or the specificity of the test.


Subject(s)
Circadian Rhythm , Cushing Syndrome/blood , Cushing Syndrome/diagnosis , Hydrocortisone/blood , Adult , Case-Control Studies , Chemistry, Clinical/standards , Chronology as Topic , Female , Humans , Male , Middle Aged , Outpatients , Reference Values , Sensitivity and Specificity
11.
Int J Obes Relat Metab Disord ; 26(4): 487-95, 2002 Apr.
Article in English | MEDLINE | ID: mdl-12075575

ABSTRACT

OBJECTIVE: To study health-related quality of life responses to marked weight loss in WHO Class II-III (body mass index (BMI) > or = 35 kg/m2) obese men. DESIGN: An 8 month randomised clinical trial with a 4 month weight loss programme (10 weeks on a very-low-energy diet (VLED) and 17 behaviour modification visits) in the treatment group and no intervention in the control group. SUBJECTS: Nineteen men (mean age 45.9 y, mean BMI 39.3 kg/m2) in the treatment group and 19 men (47.2 y, 39.4 kg/m2) in the control group. MEASUREMENTS: Weight and questionnaires measuring health-related quality of life (RAND 36-Item Health Survey 1.0 and obesity-related psychosocial problems scale). RESULTS: In the treatment group, the mean (s.d.) weight loss was 17.0 (7.4)% at the end of the 4 month therapy. At the end of follow-up, nearly 6 months after the end of VLED in the treatment group, the average maintained weight loss was 13.9 (7.8)% of baseline weight. The control group was weight stable throughout the study. During treatment, there was only transient improvement in general health, bodily pain, mental health, emotional role functioning and vitality (all increases in the scores were not statistically significant). Improvements in physical functioning, social functioning and obesity-related psychosocial problems were maintained until the end of follow-up. The treatment group also reported improvement in perceived health in the past year. There was only minor fluctuation in questionnaire scores in the control group. CONCLUSION: The short-term and maintained health-related quality of life effects of weight loss may differ. Marked weight loss in WHO Class II-III obese men leads to improvements in physical functioning, social functioning, obesity-related psychosocial problems, and perceived health; these improvements were maintained at 4 month post-intervention follow-up.


Subject(s)
Behavior Therapy , Diet, Reducing , Obesity/psychology , Obesity/therapy , Quality of Life , Weight Loss , Adolescent , Adult , Body Mass Index , Energy Intake , Finland , Health Status , Humans , Male , Middle Aged , Surveys and Questionnaires , World Health Organization
12.
Cancer Genet Cytogenet ; 128(2): 97-103, 2001 Jul 15.
Article in English | MEDLINE | ID: mdl-11463446

ABSTRACT

Genetic changes underlying the tumorigenesis of pituitary adenomas (PA) are poorly characterized. To search for characteristic genomic imbalances involved in PA, we examined 38 cases: 12 hormone-secreting (HS) and 26 non-functioning (NF) PA, by comparative genomic hybridization. The most frequent DNA copy number change in both kinds of tumors was loss of 13q. Gains of chromosomes 3, 7 and 14, 6p, and 20q were more frequent in HSPA than in NFPA. These data indicate that the 13q region may harbor tumor suppressor genes determining the tumorigenesis of PA and gain in chromosome 3 may be related to hormone secretion. These findings provide a basis to search for candidate diagnostic markers of HSPA.


Subject(s)
Adenoma/genetics , Chromosome Aberrations/genetics , Chromosomes, Human, Pair 13/genetics , Chromosomes, Human, Pair 3/genetics , Pituitary Neoplasms/genetics , Adenoma/metabolism , Adult , Aged , Chromosome Deletion , DNA, Neoplasm/genetics , Female , Gene Dosage , Humans , Male , Middle Aged , Nucleic Acid Hybridization , Pituitary Neoplasms/metabolism
14.
Ann Chir Gynaecol ; 89(4): 292-7, 2000.
Article in English | MEDLINE | ID: mdl-11204961

ABSTRACT

BACKGROUND AND AIMS: Thyroidectomy and radical cervical lymph node dissection have been suggested as primary and secondary operations aimed at achieving biochemical cure in cases of medullary thyroid carcinoma (MTC). The purpose of this study was to find out behaviour of MTC in long-term follow-up, and to estimate possible difference in biological virulence between sporadic MTC and MTC in MEN2A. MATERIAL AND METHODS: From 1967 through 1994, 39 patients with MTC, including 9 patients with hereditary disease, were operated on at the Second Department of Surgery, Helsinki University Central Hospital. Enlarged lymph nodes were dissected selectively. The main outcome measure was carcinoma-specific survival. RESULTS: In sporadic MTC, ten-year carcinoma-specific survival was 57.9% (95% CI 39.1%-76.7%) and ten-year survival after reoperation due to lymphatic node recurrence was 51.4% (CI 18.7%-84.2%). The presence of distant metastases at diagnosis (p = 0.0001) and extrathyroidal growth of the primary tumor (p = 0.0008) were independent predictors of carcinoma-specific survival in the Cox model. The risk ratio of sporadic MTC to MTC in MEN2A was 5.40 (CI 0.67-43.2) after adjusting the survival time for the size of the primary tumor. CONCLUSION: Distant metastases and the local extrathyroidal extent of the primary tumor have a significant effect on the prognosis of MTC, lymphatic node metastases and other clinical factors being less important. The biological virulence of sporadic MTC may be clinically significantly higher than that of MTC in MEN2A.


Subject(s)
Carcinoma, Medullary/mortality , Thyroid Neoplasms/mortality , Adult , Aged , Carcinoma, Medullary/complications , Carcinoma, Medullary/surgery , Female , Humans , Lymphatic Metastasis , Male , Middle Aged , Multiple Endocrine Neoplasia Type 2a/complications , Prognosis , Thyroid Neoplasms/complications , Thyroid Neoplasms/surgery , Thyroidectomy
15.
J Clin Endocrinol Metab ; 84(11): 4204-8, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10566673

ABSTRACT

Ovarian hyperstimulation caused by a gonadotroph adenoma in premenopausal women has been described only twice before this report. A 28-yr-old woman presented with menstrual disturbances and pelvic pains that began after stopping the use of contraceptive pills. Transvaginal ultrasound revealed enlarged ovaries with multiple cysts. The patient had elevated serum estradiol (up to 2900 pmol/L; normal, 80-300 pmol/L in the follicular phase) and inhibin (6.4 kU/L; normal, 0.5-2.5 kU/L) levels. Serum LH was appropriately suppressed (0.6 IU/L), but serum FSH varied from 4.9-8.1 IU/L. Both gonadotropins as well as the free alpha-subunit showed a paradoxical response to the stimulus by TRH. A nuclear magnetic resonance study unraveled a pituitary tumor, 12-14 mm in diameter, extending up to the suprasellar cistern. After pituitary surgery, all hormone values normalized, and the patient resumed regular ovulatory cycles. In immunostaining, 20-30% of the cells of the tumor stained positively for FSHbeta. We conclude that a gonadotropin-producing adenoma must be considered in the differential diagnosis of a patient presenting with large multicystic ovaries and high estradiol levels in the absence of exogenous gonadotropins.


Subject(s)
Adenoma/metabolism , Follicle Stimulating Hormone/metabolism , Ovarian Cysts/etiology , Pituitary Neoplasms/metabolism , Adenoma/complications , Adenoma/surgery , Adult , Contraceptives, Oral, Hormonal/administration & dosage , Estradiol/blood , Ethinyl Estradiol/administration & dosage , Female , Follicle Stimulating Hormone/blood , Humans , Inhibins/blood , Luteinizing Hormone/blood , Menstruation Disturbances/etiology , Norpregnenes/administration & dosage , Ovarian Cysts/blood , Ovarian Cysts/diagnostic imaging , Pituitary Neoplasms/complications , Pituitary Neoplasms/surgery , Thyrotropin/blood , Thyrotropin-Releasing Hormone , Thyroxine/blood , Ultrasonography
16.
J Intern Med ; 245(5): 463-8, 1999 May.
Article in English | MEDLINE | ID: mdl-10363746

ABSTRACT

OBJECTIVE: The main aim of the study was to evaluate the survival, well-being and working capacity of patients treated for Cushing's syndrome. DESIGN: The study was carried out by retrospectively analysing patient records from years 1981-94. Follow-up time was extended from the time of diagnosis to the end of 1996. A questionnaire dealing with symptoms prior to and after therapy, and the quality of life estimated on a Visual Analogue Scale (VAS) was sent to all surviving patients. SETTING: The study was performed in a university hospital. MAIN OUTCOME MEASURES: Survival, subjective well-being, working capacity before and after treatment and disappearance of symptoms after treatment of Cushing's syndrome. RESULTS: During the follow-up time 10 patients died out of a total of 74. The overall standardized mortality ratio (SMR) was 168% (95% CI 81-309%). The SMR of patients with pituitary disease was 267% (89-525%), and in patients with adrenal adenoma it was 135% (16-489%). Forty-six per cent of the surviving patients stated that they felt fully recovered from the disease, but the proportion of patients having persisting symptoms after treatment was also noteworthy. The mean VAS score (range 0-100) was 19 (SD 14) before treatment and 82 (SD 18) after treatment (P<0.001). After treatment, 81% of the patients were able to return to work, 11% retired because of disability, 5% retired because of age and 3% were on sick-leave at the time of answering the questionnaire. During the follow-up time, 42% of the patients with pituitary disease suffered a relapse. However, the effect of the relapse on well-being was not significant. CONCLUSIONS: The mortality risk of patients treated for Cushing's disease was not significantly increased compared with that of the general population. Many symptoms persisted even years after therapy. After clinical recovery, working ability was not always regained.


Subject(s)
Cushing Syndrome/mortality , Cushing Syndrome/psychology , Quality of Life , Adolescent , Adult , Cushing Syndrome/drug therapy , Cushing Syndrome/etiology , Female , Humans , Male , Medical Records , Middle Aged , Recurrence , Retrospective Studies , Surveys and Questionnaires , Survival Analysis , Treatment Outcome , Work Capacity Evaluation
17.
Diabetologia ; 41(11): 1253-62, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9833930

ABSTRACT

To test the hypothesis that interaction between genetic, immunological, clinical and metabolic risk factors influences the outcome of Type II (non-insulin-dependent) diabetes mellitus, we examined which of the above factors present at baseline were associated with mortality in 134 Type II diabetic patients followed for 9 years. Thirty-eight patients (29%) died during the follow-up period; the majority of whom (68%) died from cardiovascular disease. At baseline, the deceased patients had higher HbA1c values (p = 0.002), higher LDL-triglycerides (p = 0.007), lower HDL-cholesterol (p = 0.007), higher non-esterified fatty acid (NEFA) concentrations (p = 0.014), and higher albumin excretion rate (p < 0.0001) than the patients who survived. In addition, the frequency of HLA-DR4 (21 vs 39%, p = 0.048) and of parietal cell antibodies (5 vs 14%, p = 0.016) were decreased in the deceased as compared to the living patients. Patients who died during follow-up also had more retinopathy (42 vs 16%, p = 0.002), neuropathy (57 vs 23%, p < 0.001), microalbuminuria (45 vs 6%, p < 0.0001), coronary heart disease (50 vs 13%, p < 0.0001), and peripheral vascular disease (27 vs 9%, p = 0.005) at baseline than patients who survived. In a multiple logistic regression analysis macroangiopathy (p = 0.004), neuropathy (p = 0.007), HbA1c (p = 0.018) and albumin excretion rate (p = 0.016) were independent risk factors for death. In patients free of cardiovascular disease at baseline, conventional risk factors such as LDL-cholesterol (p = 0.005) and age (p = 0.003) were associated with subsequent development of cardiovascular disease. In conclusion, in addition to coexisting macroangiopathy, increased albumin excretion rate, poor glycaemic control and neuropathy are risk factors for cardiovascular mortality in patients with Type II diabetes. The presence of HLA-DR4 and signs of autoimmunity may be associated with decreased risk of cardiovascular disease.


Subject(s)
Diabetes Mellitus, Type 2/mortality , Diabetes Mellitus, Type 2/physiopathology , Diabetic Neuropathies/physiopathology , HLA-DR Antigens/blood , HLA-DR4 Antigen/blood , Adult , Aged , Albuminuria , Autoimmunity , Blood Glucose/metabolism , Cardiovascular Diseases/mortality , Cause of Death , Diabetes Mellitus, Type 2/immunology , Diabetic Angiopathies/mortality , Diabetic Angiopathies/physiopathology , Diabetic Neuropathies/mortality , Fatty Acids, Nonesterified/blood , Female , Finland/epidemiology , Follow-Up Studies , Glycated Hemoglobin/analysis , Humans , Male , Middle Aged , Registries , Regression Analysis , Risk Factors , Survival Rate , Triglycerides/blood
18.
Diabetes Care ; 21(11): 1932-8, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9802746

ABSTRACT

OBJECTIVE: Our objective was to establish the clinical, genetic, metabolic, and immunologic risk factors for the progression of the albumin excretion rate (AER) in normoalbuminuric NIDDM patients. RESEARCH DESIGN AND METHODS: We recruited 108 NIDDM patients with normal AER after a diabetes duration of 9 years to participate in a prospective 9-year follow-up. In addition to conventional clinical and metabolic variables, we assessed microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (coronary heart disease, peripheral vascular disease) diabetic complications, genetic markers (HLA genotypes), and organ-specific autoimmune markers, including islet cell antibodies. Multiple logistic regression was used to determine independent predictors of progression of AER. RESULTS: A total of 21 patients (19%) died during the follow-up. There was an overrepresentation of men (61 vs. 39%; P = 0.044) and smokers (55 vs. 27%; P = 0.01) in patients who progressed to micro- or macroalbuminuria versus those who did not progress. In addition, progressors had higher fasting plasma glucose (P = 0.002) and HbA1 (P = 0.0002) concentrations at baseline than did nonprogressors. Neuropathy was more often seen in progressors than in nonprogressors at baseline (53 vs. 16%; P = 0.0004). Frequency of HLA genotypes and autoimmune markers did not differ between progressors and nonprogressors. In a multiple logistic regression analysis, HbA1 (P = 0.0005) and a history of smoking (P = 0.011) were independent predictors of progression of AER. CONCLUSIONS: This study reemphasizes the importance of poor glycemic control and smoking as independent risk factors for progression of AER. Furthermore, development of micro- or macroalbuminuria in NIDDM was associated with neuropathy and male sex.


Subject(s)
Albuminuria/etiology , Diabetes Mellitus, Type 2/physiopathology , Adult , Aged , Biomarkers , Cohort Studies , Diabetes Mellitus, Type 2/complications , Diabetic Angiopathies/etiology , Disease Progression , Female , Histocompatibility Testing , Humans , Male , Middle Aged , Risk Factors
20.
Diabet Med ; 13(2): 165-9, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8641123

ABSTRACT

The aim of our study was to establish whether pregnancy affects long-term development and progression of retinopathy and nephropathy in diabetic women compared to nulliparous diabetic women. Twenty-eight diabetic women who had delivered in 1983-85 at Helsinki University Central Hospital and 17 nulliparous controls matched according in age, duration of diabetes, and degree of vascular complications were personally interviewed and the current retinal status and renal function were assessed 7 years later, in 1990-92. Serum creatinine, creatinine clearance, nocturnal albuminuria, and HbA1c were measured and colour fundus photography carried out. The results were compared to the status in 1983-85. Of those who had been pregnant, 5 of 26 (19.2%) had experienced worsening of retinopathy. In 3 of these, proliferative retinopathy had developed from only minimal background changes. In the control group, progression had occurred in 8 cases of 16 (50%, p < 0.05). The groups did not differ from each other regarding progression or development of nephropathy. This suggests that pregnancy does not seem to affect development or progression of diabetic nephropathy whereas progression of retinopathy seems to occur less often after pregnancy compared to nulliparous women.


Subject(s)
Diabetic Nephropathies/etiology , Diabetic Retinopathy/etiology , Pregnancy in Diabetics , Adult , Age of Onset , Disease Progression , Female , Humans , Middle Aged , Pregnancy , Retrospective Studies , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...